Fate Therapeutics Inc
FATE0.956USD
-0.007-0.76%
Fechamento 09/15, 16:00（ET）Cotações atrasadas em 15 min
109.59MValor de mercado
PerdaP/L TTM
Mais detalhes de Fate Therapeutics Inc Empresa
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Its proprietary induced pluripotent stem cells (iPSC) product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. The Company’s platform is designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Utilizing its proprietary iPSC product platform, it is advancing off-the-shelf, multiplexed-engineered natural killer (NK) cell and T-cell product candidates which are selectively designed, incorporate novel synthetic controls of cell function. Its pipeline of iPSC-derived, chimeric antigen receptor (CAR)-targeted NK cell and T-cell product candidates include FT819, FT522, FT576, FT825, FT819, FT522, and others.
Informações da empresa
Código da empresaFATE
Nome da EmpresaFate Therapeutics Inc
Data de listagemOct 01, 2013
CEODr. Bahram Valamehr, Ph.D.
Número de funcionários181
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 01
Endereço12278 Scripps Summit Drive
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92131
Telefone18588751803
Sitehttps://fatetherapeutics.com/
Código da empresaFATE
Data de listagemOct 01, 2013
CEODr. Bahram Valamehr, Ph.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Dr. Karin Jooss, Ph.D.
Dr. Karin Jooss, Ph.D.
Independent Director
Independent Director
9.85K
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Lee
Mr. Michael Lee
Independent Director
Independent Director
--
--
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Dr. Neelufar (Neely) Mozaffarian, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
617.42K
--
Dr. John D. Mendlein, J.D., Ph.D.
Dr. John D. Mendlein, J.D., Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
311.23K
--
Dr. Bahram Valamehr, Ph.D.
Dr. Bahram Valamehr, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
65.61K
-18.06%
Ms. Cindy R. Tahl, J.D.
Ms. Cindy R. Tahl, J.D.
Chief Legal and Compliance Officer, Corporate Secretary
Chief Legal and Compliance Officer, Corporate Secretary
58.39K
-13.40%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Director
Independent Director
11.33K
--
Dr. Shefali Agarwal, M.D.
Dr. Shefali Agarwal, M.D.
Independent Director
Independent Director
10.49K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
Outro
60.88%
Investidores
Investidores
Proporção
Redmile Group, LLC
11.17%
ARK Investment Management LLC
8.94%
The Vanguard Group, Inc.
7.60%
BlackRock Institutional Trust Company, N.A.
7.47%
Citadel Advisors LLC
3.94%
Outro
60.88%
Tipos de investidores
Investidores
Proporção
Investment Advisor
29.67%
Investment Advisor/Hedge Fund
27.56%
Hedge Fund
11.10%
Research Firm
6.68%
Venture Capital
3.30%
Individual Investor
1.71%
Pension Fund
0.15%
Bank and Trust
0.11%
Family Office
0.10%
Outro
19.62%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
418
107.82M
94.06%
-31.88M
2025Q1
445
110.00M
95.96%
-29.05M
2024Q4
487
105.43M
92.56%
-50.79M
2024Q3
521
119.20M
104.73%
-42.15M
2024Q2
531
125.64M
110.45%
-29.93M
2024Q1
543
126.44M
111.19%
-6.65M
2023Q4
556
99.29M
100.70%
-34.38M
2023Q3
581
100.01M
101.45%
-44.66M
2023Q2
611
113.36M
115.11%
-33.43M
2023Q1
624
117.20M
119.39%
-6.61M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Redmile Group, LLC
12.87M
11.23%
--
--
Mar 31, 2025
ARK Investment Management LLC
10.31M
9%
+10.31M
--
Mar 31, 2025
The Vanguard Group, Inc.
10.31M
8.99%
-22.58K
-0.22%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
8.39M
7.32%
-99.57K
-1.17%
Mar 31, 2025
Citadel Advisors LLC
4.29M
3.74%
-93.10K
-2.12%
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
3.38M
2.95%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.52M
2.19%
+50.85K
+2.06%
Mar 31, 2025
Baker Bros. Advisors LP
3.26M
2.84%
--
--
Mar 31, 2025
Acadian Asset Management LLC
2.47M
2.16%
+999.77K
+67.84%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.59M
2.26%
-306.82K
-10.59%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de set
Atualizado em: ter, 2 de set
Nome
Proporção
WisdomTree BioRevolution Fund
0.61%
Invesco NASDAQ Future Gen 200 ETF
0.41%
iShares Micro-Cap ETF
0.03%
iShares Russell 2000 Value ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Broad Market ETF
0%
iShares Genomics Immunology and Healthcare ETF
0%
Ver Mais
WisdomTree BioRevolution Fund
Proporção0.61%
Invesco NASDAQ Future Gen 200 ETF
Proporção0.41%
iShares Micro-Cap ETF
Proporção0.03%
iShares Russell 2000 Value ETF
Proporção0.01%
ProShares Ultra Nasdaq Biotechnology
Proporção0.01%
Invesco Nasdaq Biotechnology ETF
Proporção0.01%
iShares Biotechnology ETF
Proporção0.01%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
Schwab U.S. Broad Market ETF
Proporção0%
iShares Genomics Immunology and Healthcare ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
